Market Announcement



15 November 2024

Rhythm Biosciences Limited (ASX: RHY) – Trading Halt

Description

The securities of Rhythm Biosciences Limited ('RHY') will be placed in trading halt at the request of RHY, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Tuesday, 19 November 2024 or when the announcement is released to the market.

Issued by

ASX Compliance

Friday, 15 November 2024

Ms Melissa Kostopolous Senior Adviser, Listings Compliance Australian Securities Exchange Limited

By Email: <u>melissa.kostopolous@asx.com.au</u> tradinghaltsmelbourne@asx.com.au

Dear Melissa,

TRADING HALT REQUEST

Rhythm Biosciences Limited (ASX:RHY, ACN 619 459 335) (**Company**) requests the immediate trading halt of the Company's securities in accordance with ASX Listing Rule 7.1.

The trading halt is requested pending an announcement to the market regarding a proposed capital raising (**Purpose**).

In accordance with ASX Listing Rule 17.1, the Company provides the following information in relation to the request:

- The trading halt is necessary to assist the Company in managing its continuous disclosure obligations as the Company expects to make an announcement to the market in relation to the Purpose above.
- The Company requests the trading halt to remain in place until the earlier of commencement of normal trading on Tuesday, 19 November 2024 or when the announcement regarding the Purpose is released to the market.
- The Company expects to make the announcement regarding the Purpose to the market before the commencement of normal trading on Tuesday, 19 November 2024.
- The Company is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market about the trading halt.

This request has been approved by the Board of Rhythm Biosciences Limited.

Yours faithfully

James Barrie Company Secretary Rhythm Biosciences Limited

- ENDS -

Rhythm Biosciences Ltd ACN 619 459 335 ASX: RHY Australian Registered Address

Bio21 Molecular Science & Biotechnology Institute 30 Flemington Road Parkville VIC 3010 Australia Directors Otto Buttula Sue MacLeman Trevor Lockett Louis Panaccio David Atkins

Non-Executive Chairman Non-Executive Deputy Chair Non-Executive Director Non-Executive Director CEO & Managing Director

RHYTH BIOSCIENC

www.rhythmbio.com

T +61 3 8256 2880 E info@rhythmbio.com